REGISTER
EVOKE-03 and ADC–Immunotherapy Strategies in NSCLC: Giannis Mountzios at WCLC 2026
At WCLC 2026, Giannis Mountzios discusses the phase 3 EVOKE-03/KEYNOTE-D46 study of sacituzumab govitecan plus pembrolizumab in metastatic NSCLC with high PD-L1 expression, including efficacy results, treatment-related toxicity, discontinuations, and implications for future ADC–immunotherapy development.

At WCLC 2026, MedJ asks Giannis Mountzios about the primary results of the phase 3 EVOKE-03/KEYNOTE-D46 study and what they mean for ADC–immunotherapy development in NSCLC.

Giannis Mountzios, MD, is Director of the 4th Department of Medical Oncology and Clinical Trials Unit at Henry Dunant Hospital Center and Founder of the Oncolife Institute. Mountzios is also a member of the ESMO Educational Publications Working Group and the ESMO Young Oncologists Committee.

Mountzios discusses the study’s efficacy findings, treatment tolerability, and the clinical implications of combining sacituzumab govitecan with pembrolizumab in metastatic NSCLC with high PD-L1 expression.

Key highlights from this clip:

● EVOKE-03 compared sacituzumab govitecan plus pembrolizumab with pembrolizumab monotherapy in metastatic NSCLC with PD-L1 TPS ≥50%.

● The combination showed numerically longer median progression-free survival, but the prespecified statistical boundary was not met.

● Interim overall survival was similar between the treatment groups, at approximately 21–22 months.

● Grade ≥3 treatment-related adverse events occurred in 76.1% of patients, and 27.2% discontinued treatment because of adverse events.

● Mountzios discusses whether treatment delays, interruptions, and discontinuations may have affected efficacy outcomes.

● The interview considers future ADC–immunotherapy combinations in patients with intermediate or negative PD-L1 expression, while noting that ongoing studies are still needed.

This video is intended for medical education and professional discussion.

0
0
Loading